PMID- 33896826
OWN - NLM
STAT- MEDLINE
DCOM- 20211222
LR  - 20211222
IS  - 1875-8592 (Electronic)
IS  - 1574-0153 (Linking)
VI  - 31
IP  - 2
DP  - 2021
TI  - Repression of protocadherin 17 is correlated with elevated angiogenesis and 
      hypoxia markers in female patients with breast cancer.
PG  - 139-148
LID - 10.3233/CBM-201593 [doi]
AB  - BACKGROUND: Altered cadherin expression plays a vital role in tumorigenesis, 
      angiogenesis and tumor progression. However, the function of protocadherin 17 
      (PCDH17) in breast cancer remains unclear. OBJECTIVE: Our target is to explore 
      PCDH17 gene expression in breast carcinoma tissues and its relation to serum 
      angiopoietin-2 (Ang-2), carbonic anhydrase IX (CAIX) and % of circulating CD34+ 
      cells in breast cancer patients (BCPs). METHODS: This study included Fifty female 
      BCPs and 50 healthy females as control group. Cancerous and neighboring normal 
      breast tissues were collected from BCPs as well as blood samples at diagnosis. 
      PCDH17 gene expression was evaluated by RT-PCR. Serum Ang-2, CAIX levels were 
      measured by ELISA and % CD34+ cells were assessed by flow cytometry. RESULTS: 
      PCDH17 was downregulated in cancerous breast tissues and its repression was 
      significantly correlated with advanced stage and larger tumor size. Low PCDH17 
      was significantly correlated with serum Ang-2, % CD34+ cells and serum CAIX 
      levels. Serum CAIX, Ang-2 and % CD34+ cells levels were highly elevated in BCPs 
      and significantly correlated with clinical stage. CONCLUSIONS: PCDH17 
      downregulation correlated significantly with increased angiogenic and hypoxia 
      biomarkers. These results explore the role of PCDH17 as a tumor suppressor gene 
      inhibiting tumor growth and proliferation.
FAU - El-Benhawy, Sanaa A
AU  - El-Benhawy SA
AD  - Radiation Sciences Department, Medical Research Institute, Alexandria University, 
      Alexandria, Egypt.
FAU - Ebeid, Samia A
AU  - Ebeid SA
AD  - Applied Medical Chemistry Department, Medical Research Institute, Alexandria 
      University, Alexandria, Egypt.
FAU - Abd El Moneim, Nadia A
AU  - Abd El Moneim NA
AD  - Cancer Management and Research Department, Medical Research Institute, Alexandria 
      University, Alexandria, Egypt.
FAU - Arab, Amal R R
AU  - Arab ARR
AD  - Applied Medical Chemistry Department, Medical Research Institute, Alexandria 
      University, Alexandria, Egypt.
FAU - Ramadan, Rabie
AU  - Ramadan R
AD  - Experimental and Clinical Surgery Department, Medical Research Institute, 
      Alexandria University, Alexandria, Egypt.
LA  - eng
PT  - Journal Article
PL  - Netherlands
TA  - Cancer Biomark
JT  - Cancer biomarkers : section A of Disease markers
JID - 101256509
RN  - 0 (ANGPT2 protein, human)
RN  - 0 (Angiopoietin-2)
RN  - 0 (Antigens, CD34)
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cadherins)
RN  - 0 (PCDH17 protein, human)
RN  - EC 4.2.1.1 (CA9 protein, human)
RN  - EC 4.2.1.1 (Carbonic Anhydrase IX)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiopoietin-2/blood
MH  - Antigens, CD34/blood
MH  - Antigens, Neoplasm/blood
MH  - Breast Neoplasms/*blood supply/genetics/metabolism
MH  - Cadherins/biosynthesis/genetics/*metabolism
MH  - Carbonic Anhydrase IX/blood
MH  - Case-Control Studies
MH  - Down-Regulation
MH  - Female
MH  - Gene Expression
MH  - Humans
MH  - Middle Aged
MH  - Neovascularization, Pathologic/metabolism/pathology
OTO - NOTNLM
OT  - Ang-2
OT  - Breast cancer
OT  - CD34
OT  - PCDH17
OT  - serum CAIX
EDAT- 2021/04/27 06:00
MHDA- 2021/12/24 06:00
CRDT- 2021/04/26 05:39
PHST- 2021/04/27 06:00 [pubmed]
PHST- 2021/12/24 06:00 [medline]
PHST- 2021/04/26 05:39 [entrez]
AID - CBM201593 [pii]
AID - 10.3233/CBM-201593 [doi]
PST - ppublish
SO  - Cancer Biomark. 2021;31(2):139-148. doi: 10.3233/CBM-201593.